Semin Reprod Med 2010; 28(2): 140-146
DOI: 10.1055/s-0030-1248139
© Thieme Medical Publishers

Recent Innovations in Oral Contraception

Miriam Cremer1 , Scarlett Phan-Weston2 , Adam Jacobs1
  • 1Department of OB/GYN, The Mount Sinai Medical Center, New York, New York
  • 2Smith College, Northampton, Massachusetts
Further Information

Publication History

Publication Date:
13 April 2010 (online)

ABSTRACT

Traditional forms of oral contraception contain 21 days of hormone-containing pills and 7 days of placebo during the hormone-free interval (HFI). Since 2003, the Food and Drug Administration has approved 24/4, 84/7, and 365-day regimens. These regimens shorten the HFI in an attempt to decrease bleeding and menstrual-associated side effects. Safety and efficacy of these regimens is comparable with traditional 21/7 dosing. Extended regimens are associated with high patient satisfaction. Bleeding patterns are similar or shorter in women using extended regimens, along with improvement in menstrual symptoms. One of the new formulations contains the new progestin drospirenone, which has antimineralocorticoid and antiandrogenic properties. This review summarizes the data about new formulations of oral contraception available in the United Sates and also provides a summary of the current literature on drospirenone.

REFERENCES

Miriam Cremer, M.D. , M.P.H. 

Assistant Professor, Department of OB/GYN, The Mount Sinai Medical Center

One Gustave, L. Levy Place, Box 1170, New York, NY 10029-6574

Email: mlcremer@hotmail.com